Skip to main content
NCBI home page
Howard Hughes Medical Institute Author Manuscripts logoLink to Howard Hughes Medical Institute Author Manuscripts
. Author manuscript; available in PMC: 2009 Nov 11.
Published in final edited form as: J Immunol. 2007 May 1;178(9):5429–5433. doi: 10.4049/jimmunol.178.9.5429

Cutting Edge: Lipopolysaccharide Induces IL-10-Producing Regulatory CD4+ T Cells That Suppress the CD8+ T Cell Response

Joke M M den Haan *, Georg Kraal *, Michael J Bevan †
PMCID: PMC2776046  NIHMSID: NIHMS156225  PMID: 17442923

Abstract

TLR ligands are potent activators of dendritic cells and therefore function as adjuvants for the induction of immune responses. We analyzed the capacity of TLR ligands to enhance CD8+ T cell responses toward soluble protein Ag. Immunization with OVA together with LPS or poly(I:C) elicited weak CD8+ T cell responses in wild-type C57BL/6 mice. Surprisingly, these responses were greatly increased in mice lacking CD4+ T cells indicating the induction of regulatory CD4+ T cells. In vivo, neutralization of IL-10 completely restored CD8+ T cell responses in wild-type mice and OVA-specific IL-10 producing CD4+ T cells were detected after immunization with OVA plus LPS. Our study shows that TLR ligands not only activate the immune system but simultaneously induce Ag specific, IL-10-producing regulatory Tr1 cells that strongly suppress CD8+ T cell responses. In this way, excessive activation of the immune system may be prevented.

Dendritic cells (DCs)3 express pathogen recognition receptors, including the TLRs that allow them to be activated by microbial derived molecules. Activation of DCs by TLRs results in the up-regulation of costimulatory molecules, MHC class II molecules and the production of cytokines and chemokines (1, 2). This combined action leads to an enhanced capacity of TLR-activated DCs to stimulate naive CD8+ and CD4+ T cells which can result in autoimmunity (3–5). In the absence of microbial stimulatory agents CD8+ T cell responses are dependent on “help” provided by CD4+ T cells. This help consists of cytokines produced by helper CD4+ T cells that promote memory CD8+ T cell responses. In addition, helper CD4+ T cells “license” the DCs by CD40L-CD40 interaction (6). Licensed DCs specifically attract CD8+ T cells via chemokine release and have increased capacity to activate naive CD8+ T cells (7, 8). In contrast, CD4+ T cell help is often unnecessary for effector CD8+ T cell responses elicited by pathogens due to direct activation of DCs by pathogen recognition receptors (6).

In contrast to the helper CD4+ T cells, regulatory CD4+ T cells can down-regulate CD8+ T cell responses. The naturally occurring CD25+CD4+ Treg cells arise in the thymus and express the Foxp3 transcription factor (9). These CD25+ Foxp3+ regulatory CD4+ T cells have been shown to suppress CD8+ T cell priming and expansion in vitro as well as in vivo (10–12). Stimulation via TLRs counteracts suppressive effects of CD25+CD4+ T cells by inducing IL-6 production by DCs, causing effector T cells to become insensitive to the suppressive activity of regulatory T cells (13). The ability of TLR ligands both to activate DCs and simultaneously to alleviate the suppression by regulatory T cells can explain the proinflammatory effects of TLR ligands and their capacity to stimulate strong adaptive immune responses.

We analyzed whether the TLR ligands LPS and poly(I:C) could function as adjuvant for CD8+ T cell priming in vivo and the role of CD4+ T cells in this process. We discovered that LPS induces Ag-specific suppressor CD4+ T cells that inhibit CD8+ T cell priming via IL-10. This strongly implies that microbial activation of DCs not only results in proinflammatory adaptive immune responses, but also in the induction of regulatory T cells that down-regulate these same responses, thereby preventing overstimulation.

Materials and Methods

Mice, immunizations, and in vivo depletions

C57BL/6 mice and MHC class II-deficient mice were purchased from Taconic Farms, Charles River Laboratories, and The Jackson Laboratory. All mouse experiments were performed with the approval of the Institutional Animal Care and Use Committee at the University of Washington or at the Free University Medical Center in Amsterdam with approval of the Free University Animal Experiments Committee. Six- to 10-wk-old mice were immunized with 500 μg of OVA (Calbiochem) together with 30 μg of LPS (026:B6; Sigma-Aldrich) or 100 μg of poly(I:C) (Sigma-Aldrich). To deplete CD4+ cells, 200–300 μg of GK1.5 mAb was injected i.p. on day −4, −2, and +3 of the day of immunization. The efficiency of depletion was minimally 98.5% for CD4+ depletion. To deplete CD25+ cells, 25–50 μg of PC61 mAb was injected i.p. on day −4 or −3 of the day of immunization. The efficiency of depletion was determined with staining with Abs 7D4 and PC61 that recognize non-competing epitopes on CD25. No residual staining with PC61 could be detected whereas the efficiency of depletion analyzed with 7D4 was 91%. Neutralization of IL-10 in vivo was achieved by injections with JES5–2A5 on day −6 (300 μg), −2 (300 μg), day 0 (500 μg), and day +4 (300 μg), of the day of immunization.

Intracellular cytokine staining

Intracellular cytokine staining was performed essentially as described (14); 3 × 106 splenocytes/well were plated in 96-well plates in the presence of 1 μl/ml brefeldin A (GolgiPlug, Cytofix/Cytoperm kit; BD Pharmingen) and 0.1 μg/ml OVA257–264 peptide for 5 h at 37°C. Following the incubation, cells were stained with CD11a-FITC and CD8-PE, permeabilized and stained for intracellular cytokine expression using IFN-γ-allophycocyanin (BD Pharmingen) and reagents provided in the Cytofix/Cytoperm kit according to the manufacturer's instructions (BD Pharmingen).

Cytotoxicity assay

Splenocytes (50 × 106) were restimulated in 20 ml of complete IMDM together with 2.5 × 106 irradiated embryonic fibroblasts transfected with OVA257–264, H-2Kb, and CD80 (15). Five days after restimulation a cytotoxicity assay was performed following standard procedures using EL-4 cells coated with or without OVA257–264 as target cells.

IL-10 ELISA

Splenocytes were restimulated in 96-well flat bottom plates at 0.75 × 106/well in 200 μl of complete IMDM with 100 μg/ml OVA protein (Calbiochem or Seikagaku), with 1 μg/ml OVA257–264 or with 100 μg/ml OVA323–339 or OVA262–276 peptide. After 4 days of culture, supernatants were tested for IL-10 content by ELISA according to the manufacturer's instructions (BD Biosciences). To deplete B220+, CD8+, or CD4+ cells from total splenocytes, cells were incubated for 20 min with Abs RA3-6B2, 53.6.7 or GK1.5, respectively. The cells were further depleted using anti-rat Dynal beads following the manufacturer's instructions (Dynal Biotech).

Results

TLR ligands stimulate increased CD8+ T cell responses in the absence of CD4+ T cells

Intravenous injection of protein Ag generally results in induction of T cell tolerance, because the Ag is then presented by non-activated DCs, which precludes priming of T cell responses. To determine whether TLR ligand stimulation of DCs would result in efficient CD8+ T cell responses, we immunized mice i.v. with OVA either alone or in the presence of TLR-4 and -3 ligands LPS or poly(I:C) (Fig. 1, A and B). There was no detectable CD8+ T cell response to OVA alone, but immunization with OVA plus LPS, or OVA plus poly(I:C), activated OVA-specific CD8+ T cells in wild-type C57BL/6 mice as well as in MHC class II-deficient mice, which lack CD4+ T cells. Apparently, activation of splenic DCs by these TLR ligands, as can be detected by up-regulation of costimulatory molecules (data not shown), is sufficient for CD8+ T cell priming and makes CD4+ T cell help unnecessary. Surprisingly and consistently, compared with wild-type mice, higher CD8+ T cell responses were observed in MHC class II-deficient mice and in mice that were depleted of CD4+ T cells by opsonizing Ab (Fig. 1C). CD8+ T cells activated in the absence of CD4+ T cells could be efficiently restimulated in vitro and showed strong cytotoxic activity (Fig. 1D), illustrating that these cells did not exhibit the “helpless” phenotype of CD8+ T cells destined to die after restimulation (15). Together these experiments indicated that CD4+ T cells in wild-type mice exerted a significant suppressive effect on CD8+ T cells after priming with OVA plus LPS or poly(I:C).

Figure 1.

Figure 1

Open in a new tab

TLR agonists promote higher CD8+ T cell responses in the absence of CD4+ T cells. A, C57BL/6 and MHC class II-deficient mice were immunized with 500 μg of OVA either alone or plus 30 μg of LPS or 100 μg of poly(I:C). Seven days after immunization the OVA-specific CD8+ T cell response was determined by intracellular IFN-γ staining. FACS plots are gated on CD8+ T cells, and the number displayed indicate the percentage of CD11a+IFN-γ-producing cells. B, Average OVA-specific CD8+ T cell response in C57BL/6 and MHC class II-deficient mice. The percentage of CD11a+IFN-γ-producing cells out of total CD8+ T cells is depicted. Error bars display SEM, n = 3, and results are representative of two independent experiments for poly(I:C) and five independent experiments for LPS. C, C57BL/6, MHC class II-deficient and CD4-depleted C57BL/6 mice were immunized with OVA plus LPS, and on day 7 the frequency of OVA specific CD8+ T cells was assessed by IFN-γ staining. The percentage of CD11a+IFN-γ-producing cells out of total CD8+ T cells is depicted. Results are representative of five independent experiments with 2–4 mice. D, Splenocytes from C were restimulated in vitro and their cytotoxic capacity evaluated by 51Cr release assay. The average cytotoxicity of two mice is depicted. Error bars display SEM.

In vivo suppression of CD8+ T cells is mediated via IL-10

In several different experimental systems CD25+ Treg have been shown to suppress CD8+ T cell responses (10, 11). To investigate whether CD25+ CD4+ T cells suppressed the CD8+ T cell response, we depleted mice of CD25+ cells and immunized with OVA plus LPS. Although the CD25+ CD4+ T cells were efficiently depleted (Fig. 2A), the OVA-specific CD8+ T cell response was only partially increased compared with control IgG-treated mice (Fig. 2B), suggesting that in addition to CD25+ CD4+ T cells other types of regulatory CD4+ T cells were responsible for the CD8+ T cell suppression. Ag-specific regulatory CD4+ T cells can be elicited in the periphery by antigenic stimulation in the presence of high concentrations of IL-10 (16, 17). These Tr1 cells do not express CD25 or Foxp3 and mediate their suppression via IL-10 (18, 19). They have been shown to suppress effector CD4+ T responses in a number of models, but less is known of their effects on CD8+ T cells (20). To determine whether IL-10 was important for the CD8+ T cell suppression, we neutralized IL-10 in vivo by injecting a neutralizing Ab. When IL-10 was neutralized we observed a strong CD8+ T cell response in wild-type mice after immunization with OVA plus LPS that was equivalent to that seen in the absence of CD4+ T cells (Fig. 2C). These results together indicated that IL-10 was necessary for the CD8+ T cell suppression and that in addition to CD25+ CD4+ Tregs other regulatory CD4+ T cells were involved.

Figure 2.

Figure 2

Open in a new tab

Suppression of CD8+ T cell priming is mediated via IL-10. A, C57BL/6 mice were treated with control rat IgG or PC61 Ab. On the day of immunization, blood of depleted mice was analyzed. FACS profiles show CD4+ gated cells stained with anti-CD25 Abs 7D4 and PC61. One representative mouse of each group is shown. B, MHC class II-deficient mice and C57BL/6 mice treated with control rat IgG or depleted of CD25+ cells were immunized with OVA plus LPS, and on day 7 the number of OVA-specific CD8+ T cells was determined by intracellular IFN-γ staining. The percentage of CD11a+IFN-γ-producing cells out of total CD8+ T cells is depicted. n = 11 from four separate experiments, error bars display SEM. C, C57BL/6 treated with control rat IgG, or depleted of CD4+ cells or treated with neutralizing anti-IL-10 Ab were immunized with OVA plus LPS and the number of OVA-specific CD8+ T cells was determined by intracellular IFN-γ staining. The percentage of CD11a+IFN-γ producing cells out of total CD8+ T cells is depicted. n = 6 from two separate experiments and error bars display SEM.

LPS induces Ag-specific Tr1 in vivo

To determine whether Ag-specific Tr1 cells were induced, splenocytes from wild-type mice and MHC class II-deficient mice previously immunized with OVA plus LPS were restimulated with OVA in vitro, and supernatants were analyzed for IL-10. OVA-induced IL-10 was detected in cultures derived from wild-type mice but not in those from MHC class II-deficient mice (Fig. 3A) and IL-10 production in wild-type splenocytes was completely abolished after removal of CD4+ T cells (Fig. 3B). This strongly suggested that Ag recognition by CD4+ T cells resulted in IL-10 production. Finally, we tested the known MHC class I and II epitopes from OVA for IL-10 production and found that only restimulation with the MHC class II epitope OVA262–276 resulted in strong IL-10 production (Fig. 3C). Together these experiments show that OVA-specific IL-10-producing CD4+ T cells are induced by immunization with OVA plus LPS.

Figure 3.

Figure 3

Open in a new tab

Immunization with OVA plus LPS induces OVA-specific IL-10-producing cells. A, C57BL/6 and MHC class II-deficient mice were immunized with OVA plus LPS. On day 7, splenocytes were isolated and restimulated with medium, 0.1 mg/ml OVA, or 100 ng/ml LPS. The IL-10 was measured in day 4 supernatants by ELISA. n = 3 and error bars display SEM. Results are representative of three independent experiments. B, Total splenocytes isolated from C57BL/6 mice immunized with OVA plus LPS were depleted for B220+, CD4+, or CD8+ cells and restimulated with OVA protein. IL-10 was analyzed after 4 days. n = 3 and error bars display SEM. C, Splenocytes isolated from C57BL/6 mice that had been immunized with OVA plus LPS 7 days previously were restimulated with OVA protein, OVA 257-264 peptide, OVA 323-339 peptide, or OVA 262-276 peptide. IL-10 was analyzed after 4 days. n = 3 and error bars display SEM. Results are representative of four independent experiments.

Discussion

The present study shows that immunization with TLR ligands induces Ag-specific IL-10-producing CD4+ T cells that strongly suppress CD8+ T cell responses in vivo. A number of studies have previously shown that TLR ligands can function as adjuvant for CD8+ T cell responses especially in synergy with each other or when combined with anti-CD40 ligation (21–23). Our data indicate that although TLR ligands are strong adjuvants for the induction of CD8+ T cell responses, they simultaneously initiate a suppressive mechanism via IL-10 producing CD4+ T cells.

IL-10 is a well-known anti-inflammatory cytokine that suppresses DC Ag presentation and the production of proinflammatory cytokines such as IL-12 p70 (24). Boonstra et al. (25) demonstrated that macrophages and DCs produced significant amounts of IL-10 after stimulation with TLR ligands and that IL-12 p70 production was strongly suppressed by this endogenous IL-10 production. Especially the splenic CD8+ DC subset was highly regulated by IL-10. This CD8+ DC subset has also recently been shown to be specialized for MHC class I presentation to CD8+ T cells (26). Our study shows that IL-10 is an important inhibitor of CD8+ T cell responses in vivo, which is in contrast with initial studies in which IL-10 was shown to enhance proliferation and cytotoxic capacity of CD8+ T cells (24). However, our study is consistent with recent in vivo studies that showed that IL-10 is produced during chronic viral infection with profound suppressive effects on the protective CD8+ T cell response (27, 28). Together these and our studies clearly point to a suppressive role for IL-10 with regard to CD8+ T cell priming in vivo and also imply that blockade of IL-10 function in vivo may be of therapeutic interest for the development of vaccines based on CD8+ T cell immunity.

In addition to the autocrine suppressive effects of IL-10 on APCs, high levels of IL-10 also are known to lead to the generation of suppressive Tr1 cells, which in turn are characterized by the production of IL-10. Tr1 cell generation has been demonstrated in several human and murine in vitro and in vivo model systems (20). Here we show that TLR4 signaling by LPS results in Tr1 induction and CD8+ T cell suppression in vivo. Similarly, Bordetella pertussis stimulates IL-10 production and Tr1 generation via TLR4 signaling (29). In this model, IL-10 production and Tr1 generation was essential for limiting inflammatory pathology in the lungs after B. pertussis infection. Also in other infectious models, IL-10 was found to prevent exacerbation of inflammation and disease (30). Apparently, IL-10 and Tr1 cells serve as a protective strategy for the host to prevent excessive damage by the host adaptive response.

TLR ligands are being evaluated in many vaccination studies because of their excellent capacity to activate DCs. We now show that TLR ligands not only function as adjuvant for CD8+ T cell priming, but that they also induce IL-10 producing Tr1 cells which in turn results in suppression of CD8+ T cell activation. These observations should be taken into account when considering TLR containing adjuvants for the priming of CD8+ T cell responses for vaccination purposes.

Footnotes

1

Supported by grants from the Netherlands Organization of Scientific Research and the Howard Hughes Medical Institute.

3

Abbreviations used in this paper: DC, dendritic cell; Treg, regulatory T cell.

Disclosures

The authors have no financial conflict of interest.

References

  • 1.Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124:783–801. doi: 10.1016/j.cell.2006.02.015. [DOI] [PubMed] [Google Scholar]
  • 2.Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440:808–812. doi: 10.1038/nature04596. [DOI] [PubMed] [Google Scholar]
  • 3.Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA. 2002;99:351–358. doi: 10.1073/pnas.231606698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Lang KS, Recher M, Junt T, Navarini AA, Harris NL, Freigang S, Odermatt B, Conrad C, Ittner LM, Bauer S, et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med. 2005;11:138–145. doi: 10.1038/nm1176. [DOI] [PubMed] [Google Scholar]
  • 5.Hamilton-Williams EE, Lang A, Benke D, Davey GM, Wiesmuller KH, Kurts C. Cutting edge: TLR ligands are not sufficient to break cross-tolerance to self-antigens. J Immunol. 2005;174:1159–1163. doi: 10.4049/jimmunol.174.3.1159. [DOI] [PubMed] [Google Scholar]
  • 6.Williams MA, Bevan MJ. Effector and memory CTL differentiation. Annu Rev Immunol. 2006 November 26; doi: 10.1146/annurev.immunol.25.022106.141548. Epub ahead of print. [DOI] [PubMed] [Google Scholar]
  • 7.Castellino F, Huang AY, Altan-Bonnet G, Stoll S, Scheinecker C, Germain RN. Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006;440:890–895. doi: 10.1038/nature04651. [DOI] [PubMed] [Google Scholar]
  • 8.Smith CM, Wilson NS, Waithman J, Villadangos JA, Carbone FR, Heath WR, Belz GT. Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity. Nat Immunol. 2004;5:1143–1148. doi: 10.1038/ni1129. [DOI] [PubMed] [Google Scholar]
  • 9.Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol. 2005;6:345–352. doi: 10.1038/ni1178. [DOI] [PubMed] [Google Scholar]
  • 10.Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol. 2001;167:1137–1140. doi: 10.4049/jimmunol.167.3.1137. [DOI] [PubMed] [Google Scholar]
  • 11.Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med. 2001;194:823–832. doi: 10.1084/jem.194.6.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, et al. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591–2601. doi: 10.4049/jimmunol.174.5.2591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science. 2003;299:1033–1036. doi: 10.1126/science.1078231. [DOI] [PubMed] [Google Scholar]
  • 14.Williams MA, Bevan MJ. Shortening the infectious period does not alter expansion of CD8 T cells but diminishes their capacity to differentiate into memory cells. J Immunol. 2004;173:6694–6702. doi: 10.4049/jimmunol.173.11.6694. [DOI] [PubMed] [Google Scholar]
  • 15.Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 2003;421:852–856. doi: 10.1038/nature01441. [DOI] [PubMed] [Google Scholar]
  • 16.Battaglia M, Gregori S, Bacchetta R, Roncarolo MG. Tr1 cells: from discovery to their clinical application. Semin Immunol. 2006;18:120–127. doi: 10.1016/j.smim.2006.01.007. [DOI] [PubMed] [Google Scholar]
  • 17.O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10:801–805. doi: 10.1038/nm0804-801. [DOI] [PubMed] [Google Scholar]
  • 18.Vieira PL, Christensen JR, Minaee S, O'Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC, O'Garra A. IL-10-secreting regulatory T cells do not express Foxp3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 2004;172:5986–5993. doi: 10.4049/jimmunol.172.10.5986. [DOI] [PubMed] [Google Scholar]
  • 19.Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005;105:1162–1169. doi: 10.1182/blood-2004-03-1211. [DOI] [PubMed] [Google Scholar]
  • 20.Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006;212:28–50. doi: 10.1111/j.0105-2896.2006.00420.x. [DOI] [PubMed] [Google Scholar]
  • 21.Schwarz K, Storni T, Manolova V, Didierlaurent A, Sirard JC, Rothlisberger P, Bachmann MF. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol. 2003;33:1465–1470. doi: 10.1002/eji.200323919. [DOI] [PubMed] [Google Scholar]
  • 22.Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004;199:775–784. doi: 10.1084/jem.20031591. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol Cell Biol. 2004;82:596–602. doi: 10.1111/j.0818-9641.2004.01285.x. [DOI] [PubMed] [Google Scholar]
  • 24.Moore KW, de Waal MR, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol. 2001;19:683–765. doi: 10.1146/annurev.immunol.19.1.683. [DOI] [PubMed] [Google Scholar]
  • 25.Boonstra A, Rajsbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira JP, Bates EE, Akira S, Vieira P, Liu YJ, et al. Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol. 2006;177:7551–7558. doi: 10.4049/jimmunol.177.11.7551. [DOI] [PubMed] [Google Scholar]
  • 26.Dudziak D, Kamphorst AO, Heidkamp GF, Buchholz VR, Trumpfheller C, Yamazaki S, Cheong C, Liu K, Lee HW, Park CG, et al. Differential antigen processing by dendritic cell subsets in vivo. Science. 2007;315:107–111. doi: 10.1126/science.1136080. [DOI] [PubMed] [Google Scholar]
  • 27.Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MB. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12:1301–1309. doi: 10.1038/nm1492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ejrnaes M, Filippi CM, Martinic MM, Ling EM, Togher LM, Crotty S, von Herrath MG. Resolution of a chronic viral infection after interleukin-10 receptor blockade. J Exp Med. 2006;203:2461–2472. doi: 10.1084/jem.20061462. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Higgins SC, Lavelle EC, McCann C, Keogh B, McNeela E, Byrne P, O'Gorman B, Jarnicki A, McGuirk P, Mills KH. Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol. 2003;171:3119–3127. doi: 10.4049/jimmunol.171.6.3119. [DOI] [PubMed] [Google Scholar]
  • 30.O'Garra A, Vieira PL, Vieira P, Goldfeld AE. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest. 2004;114:1372–1378. doi: 10.1172/JCI23215. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES